H2020Докторантска мрежа2015–2018

TOLLerant · Toll-Like Receptor 4 activation and function in diseases: an integrated chemical-biology approach.

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2015-01-01 → 2018-12-31
Финансиране от ЕС
3 122 539 €
Участници
10
Схема
MSCA-ITN-ETN

Линиите свързват координатора с партньорите.

Накратко на български

Рецепторите TLR4 и начинът, по който се активират или блокират чрез синтетични молекули и наночастици, са в центъра на анализа. Това помага за разработването на нови противовъзпалителни лекарства, ваксини и методи за имунотерапия при рак.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Toll-Like Receptor 4 activation and function in diseases: an integrated chemical-biology approach.

The TOLLerant project aimed to address the medical and societal need of new anti-inflammatory drugs against infectious and non-infectious inflammatory diseases. New therapeutic approaches have been explored, based on the use of small-molecular TLR4 modulators, whose production could be scaled to an industrial level. This goal was achieved during the four years of project by the cooperative effort of a multidisciplinary consortium composed of 13 early stage researchers recruited by 8 teams from universities and 2 from companies located in different countries (Italy, Spain, Slovenia, Germany and Belgium). Conclusions of the action: The short term scientific objective of the project has been the study of molecular aspects of TLR4 activation and inhibition by using selective agonists and antagonists obtained by chemical synthesis or extracted from natural sources. This objective has been realized. Several New Chemical Entities (NCAs) were synthesized and delivered during the project (new synthetic molecules, new LPS variants from bacteria, nanoparticles functionalized with molecules). Some TLR4 antagonists were patented. The activity of these NCAs on TLR4 has been validated in vitro (binding experiments, microscopy, and experiments on human and murine cells) and in vivo in animal models of sepsis and LPS-induced pneumonia. The NCAs produced in a collaborative way within the TOLLerant consortium are an important hit for drug development in the field of anti-inflammatory drugs, vaccine adjuvants, and substances for tumor immunotherapy. The delivery of NCAs therefore partially meets the long-term scientific objective of TOLLerant (develop specific drug hits based on small molecules and nanoparticles targeting TLR4). The educational objective of the project has been to train the 13 early stage researchers hired by the consortium, providing them with scientific knowledge and industrial skills. During the 4 years project, the two companies collaborated with the academic groups of the TOLLerant consortium with the main objective to train 13 young scientists as the future leaders of the field to work in a multidisciplinary environment and to develop specific scientific, industrial and soft skills. The young ESRs have been the real driving force of the basic science developed during the project. Several new projects and new ideas derived from brainstorming among ESRs and PIs during the network meetings. ESRs also greatly contributed to the spreading of results in the scientific community and to the communication and dissemination activities directed to the general public and to the society.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Based on an international team derived from the COST action BM1003 (www.cost-bm1003.info, 2011-2014) and thus relying on consolidated group interactions and synergies and on a unique combination of chemistry, biology, biophysics, biochemistry and pharmacology expertise, the TOLLerant project aims to gain information on molecular aspects of TLR4 activation and signaling by using synthetic and natural compounds and nanoparticles that interact selectively with some components (mainly MD-2 and CD14) of the TRL4 recognition system. TLR4 is an emerging molecular target related to an impressively broad spectrum of modern day disorders still lacking specific pharmacological treatment. These include autoimmune disorders, chronic inflammations, allergies, asthma, infectious and CNS diseases and cancer. The short-term scientific objective is to develop novel, non-toxic, synthetic and natural TLR4 modulators (agonists or antagonists) and to assess their therapeutic potential on animal models of TLR4-related acute and chronic pathologies that still lack efficient pharmacological treatment. The long-term scientific objective is to develop a new generation of innovative, TLR4-based therapeutics, to be used as vaccine adjuvants, anti-sepsis agents, and anti-inflammatory agents to treat chronic inflammations (allergy, asthma). The training programme will provide Early Stage Researchers (ESR) with broad competences, experience and skills in the cutting-edge, inter-disciplinary research in the field of chemical biology related to the molecular mechanisms of innate immunity and inflammation. During the training, the young researchers will be supported by senior scientists to cultivate their scientific, entrepreneurial and inter-cultural mindset. The non-academic sector will be committed to provide ESRs with entrepreneurship and company management skills, in order to enhance their employability by the private sector or even to motivate them to create own start-up companies.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз